Enclomiphene and GLP-1: How It Differs From TRT

Enclomiphene has become a common talking point in men’s health, usually mentioned as an alternative to testosterone replacement. If you are on a GLP-1 or considering one and thinking about your testosterone, it is worth understanding what enclomiphene actually is, how it differs from TRT, and where it stands with the FDA before you make any decisions.

As with the rest of this section, this is educational. Transformation Health is an independent publisher; it does not provide medical care, prescribe, or sell enclomiphene, testosterone, or GLP-1 medications. The aim is to help you ask better questions of the licensed provider who would manage it.

What enclomiphene is

Enclomiphene is a selective estrogen receptor modulator, the trans-isomer of a medication called clomiphene. Rather than supplying testosterone from outside the body, it works upstream: it prompts the brain and pituitary to send stronger signals to the testicles, which increases the body’s own testosterone production^[1].

That mechanism is the whole point. Testosterone replacement therapy replaces the hormone directly, which works but tells the body it can stop making its own. Enclomiphene instead pushes the body’s natural production to do more of the work itself.

The headline difference: fertility

The reason enclomiphene gets so much attention is fertility, and it is a genuinely important distinction.

Testosterone supplied from outside the body suppresses the internal signals that drive sperm production, so TRT can reduce fertility, sometimes significantly. Enclomiphene works by stimulating your own system rather than overriding it. In randomized trials run by its developer, enclomiphene raised testosterone while sperm counts stayed in the normal range, whereas men on testosterone gel saw sperm counts fall^[2][3]. Those trials were short, about 16 weeks in the larger studies, so longer-term effects are less clear. For a man who wants to raise his testosterone but keep the option of fathering children, that difference is often the deciding factor.

This is exactly the kind of tradeoff to weigh with a provider before choosing a path, and it is covered from the other direction in Testosterone Therapy (TRT) and GLP-1.

Its FDA status, and why it matters

Here is the part that fits the theme of this whole section: know what you are actually taking.

Enclomiphene is not an FDA-approved drug. Its developer pursued approval, but neither the FDA nor the European Medicines Agency approved it, and development was discontinued in 2021^[1][4]. As of October 16, 2026, the FDA’s Drugs@FDA database lists no approved application for enclomiphene^[5]. Clomiphene, the related compound it comes from, is FDA-approved to treat ovulation problems in women and is used off-label in men^[1]. Products sold as enclomiphene are compounded or otherwise unapproved. That does not make them inherently unsafe, but it does mean the FDA has not reviewed them for safety, effectiveness, or quality, there is no FDA-reviewed label listing side effects and warnings, and quality and dosing can vary by source. In a 2026 position statement, the British Society for Sexual Medicine pointed to the lack of long-term efficacy and safety data and advised limiting its use to experienced clinicians^[4].

The practical takeaway is to treat the source seriously. A careful provider who tests, prescribes, and monitors is a very different thing from a subscription clinic that ships a compounded product with minimal oversight. Ask directly where it comes from and how you will be monitored.

How it fits with a GLP-1

No specific interaction between enclomiphene and GLP-1 medications has been documented, largely because the combination has not been studied, and they target different things: enclomiphene works on testosterone, and the GLP-1 supports weight management.

Two practical notes matter. First, enclomiphene is taken by mouth, and GLP-1 medications slow gastric emptying, which the prescribing information says can affect how oral medications taken at the same time are absorbed^[6]. We found no published study of enclomiphene taken with a GLP-1, so the size of any effect is unknown. It is the same consideration described in GLP-1 and Birth Control, and it is worth asking your provider about timing. Second, coordinate. Enclomiphene and your GLP-1 will likely come from different providers, so each needs your full medication list.

The weight connection you should not miss

It would be a mistake to think about enclomiphene without the weight piece, because they are linked.

Enclomiphene is not a weight loss medication, and you should not expect it to act like one. But excess weight is strongly associated with lower testosterone in men, and in a meta-analysis of studies on diet and bariatric surgery, losing weight was associated with higher testosterone, with larger losses linked to larger rises^[7]. Results vary. That means a GLP-1 plan that helps you lose weight may improve your testosterone at the source, which is worth understanding before you assume a testosterone medication is the only answer. For some men, addressing the weight does a meaningful share of the work.

The bottom line

Enclomiphene raises the body’s own testosterone rather than replacing it, and its headline difference from TRT is fertility: in its developer’s short-term trials, sperm counts held steady while testosterone gel lowered them. It is not FDA-approved, products sold as enclomiphene are compounded or otherwise unapproved, and long-term safety data are limited, so the source and monitoring matter. It can be considered alongside a GLP-1 with provider coordination and a note about oral-medication timing, but it is not a weight loss treatment. And because weight itself drives testosterone in men, the weight loss side of your plan may be doing more for your levels than you expect.

What to read next

For the fuller picture on testosterone and the weight connection, read Testosterone Therapy (TRT) and GLP-1. For reproductive health specifically, see GLP-1 Medications and Fertility. And for the full section on what to combine with a GLP-1, see the Supplements and Interactions With GLP-1 overview.

Citations

[1] Earl JA, Kim ED. “Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism.” Expert Review of Endocrinology and Metabolism 2019;14(3):157-165. https://pubmed.ncbi.nlm.nih.gov/31063005/ (Enclomiphene is the trans-isomer of clomiphene, which is FDA-approved for ovarian dysfunction; reviews the difficulties with FDA approval of enclomiphene.)

[2] Wiehle RD, Fontenot GK, Wike J, et al. “Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone.” Fertility and Sterility 2014;102(3):720-727. https://pubmed.ncbi.nlm.nih.gov/25044085/ (Phase II trial run by the developer; testosterone rose and sperm counts were conserved on enclomiphene.)

[3] Kim ED, McCullough A, Kaminetsky J. “Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement.” BJU International 2016;117(4):677-685. https://pubmed.ncbi.nlm.nih.gov/26496621/ (Two 16-week phase III trials; sperm concentration stayed in the normal range on enclomiphene and fell markedly on testosterone gel.)

[4] Foster J, Choo L, Patel A, et al. “British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male Hypogonadism.” World Journal of Men’s Health 2026;44(3):480-483. https://pubmed.ncbi.nlm.nih.gov/41714894/ (Not approved by the FDA or EMA; development discontinued in 2021; may be available through compounding pharmacies; long-term efficacy and safety data are lacking.)

[5] U.S. Food and Drug Administration. Drugs@FDA database, searched October 16, 2026. https://www.accessdata.fda.gov/scripts/cder/daf/ (No approved application listed for enclomiphene.)

[6] Semaglutide injection 2.4 mg and tablets, FDA prescribing information (NDA 215256), revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Delayed gastric emptying may affect absorption of oral medications taken at the same time.)

[7] Corona G, Rastrelli G, Monami M, et al. “Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis.” European Journal of Endocrinology 2013;168(6):829-843. https://pubmed.ncbi.nlm.nih.gov/23482592/ (Weight loss by diet or bariatric surgery was associated with higher testosterone; greater weight loss was linked to larger rises.)